GENUS ONCOLOGY

Genus Oncology was formed in 2007 with a mission of discovering, developing, and commercializing new anti-cancer agents that target the Mucin 1 (MUC1) oncoprotein. The incidence of overexpressed MUC1 in a wide array of carcinomas and hematologic malignancies has been known by researchers for many years. Until now, no viable approach existed to selectively target and block the function of MUC1 that leads to the formation of tumors.